Compositions and methods for inhibiting brain trauma-induced neurodegeneration and related conditions

A method for inhibiting brain trauma-induced neurodegeneration and conditions resulting therefrom, the method comprising:

• administering an extended, controlled-release medicament to a patient subsequent to a brain injury event, the extended, controlled-release medicament comprising:
• an active compound comprising one or more of:
• phenserine, a phenserine metabolite, a phenserine prodrug, or combinations thereof;
• and
• one or more pharmaceutically acceptable excipients;
• and
• maintaining in the patient, over a period of time following the brain injury event, a therapeutically effective concentration of the active compound sufficient to:
• (i) inhibit, attenuate, or prevent onset or progression of anecrotic or preprogrammed cell death in neurons following the brain injury event;
• (ii) inhibit, attenuate, or prevent brain trauma-induced neurodegeneration and/or conditions resulting therefrom;
• and/or
• (iii) reduce risk of developing a neurodegenerative disorder following the brain injury event.

A method for inhibiting brain trauma-induced neurodegeneration and conditions resulting therefrom, the method comprising administering at least a daily dose of a composition to a patient subsequent to a brain trauma, the composition comprising:

• an active compound comprising one or more of:
• phenserine, a phenserine metabolite, a phenserine prodrug, or combinations thereof;
• and
• one or more pharmaceutically acceptable excipients, wherein the one or more pharmaceutically acceptable excipients are combined with the active compound to form an extended, controlled-release medicament that delivers the active compound over a period of time.

A method for treating a brain injury event, the method comprising administering at least a daily dose of a composition to a patient subsequent to a brain injury event, the composition comprising:

• an active compound comprising one or more of:
• phenserine, a phenserine metabolite, a phenserine prodrug, or combinations thereof;
• and
• one or more pharmaceutically acceptable excipients, wherein the one or more pharmaceutically acceptable excipients are combined with the active compound to form an extended, controlled-release medicament that delivers the active compound over a period of time.